BSECompany Update3 Nov 2026 · 3 Nov 2026, 02:01 pm

Newspaper Publication of Unaudited Financial Results for the quarter and half year ended 30th September 2026

Chemcrux Enterprises Ltd · 540395

✦ AI SummaryResults

Chemcrux Enterprises Ltd and Akums Drugs and Pharmaceuticals Ltd have published unaudited financial results for the quarter and half year ended September 30, 2026, with details available on their respective websites and BSE.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Chemcrux Enterprises Ltd - 540395 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Attachments (1)

📄

36569274-b0b2-431d-8227-b16d393e444c.pdf

pdf

Download →
View document text
03rd November 2026 BSE LIMITED Phiroze Jeejeebhoy Towers Department of Corporate Services Dalal Street, Mumbai- 400 001 Dear Sir/Madam Subject: Newspaper Publication of Standalone & Consolidated Unaudited Financial Results for the quarter and half year ended 30th September 2026 Ref: BSE Scrip ID: CHEMCRUX BSE Scrip Code: 540395 Pursuant to Regulation 30 & 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed newspaper publication of Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 published in Financial Express (English & Gujarati Edition) today i.e., 03rd November 2026. Kindly take the above on your record. Yours faithfully For CHEMCRUX ENTERPRISES LIMITED Dipika Rajpal Company Secretary & Compliance Officer Enclosed: As above HEC INFRA PROJECTS LIMITED RegisteredOffice:Sigma-1Corporates,CorporateHouseNo.6,SindhuBhavanRoad, Nr.MaanPartyPlotCrossRoad,Bodakdev,Ahmedabad-380054,Gujarat. Phone:+91-79-40086771-74,E:elect@hecproject.com,W:www.hecprojects.in, CIN:L45200GJ2005PLC046870 UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2026 TheBoardofDirectorsintheirmeetingheldon2ndNovember2026,haveapproved andtakenonrecordtheUnauditedFinancialResultsforthequarterendedon30th September,2026intermsofRegulation33oftheSEBI(LODR)Regulations,2015. The aforesaid Unaudited Financial Results for the quarter ended 30th September, 2026 along with Limited Review Report thereon are available on website of NSE Limited at www.nseindia.com and also on Company website and can also be accessedbyscanningbelowQuickResponseCode: ForandonbehalfoftheBoardofDirectorsof HECInfraProjectsLimited SD/- Place:Ahmedabad GaurangShah-(ManagingDirector) Date :2ndNovember2026 DIN:01756079 DEVYANI INTERNATIONAL LIMITED CorporateIdentificationNumber:L15135HR1991PLC143853 Registered&CorporateOffice: Plot No. 18, Sector – 35, Gurugram – 122004, Haryana Tel: +91-124-4566300, E-mail: companysecretary@dil-rjcorp.com, Website: www.dil-rjcorp.com Statement of Standalone and Consolidated financial results for the Quarter and Half Year ended 30 September 2026 [Regulation 33 read with Regulation 47 (1) (b) of the SEBI (LODR) Regulations, 2015] The Board of Directors of the Company at its meeting held on 2 November 2026 inter-alia considered and approved the Unaudited Financial Results of the Company (Standalone and Consolidated) for the Quarter and Half Year ended 30 September 2026. (‘Financial Results’) The Financial Results along with the Limited Review Reports, have been disseminated on the Company’s website at https://dil-rjcorp.com/wp- content/uploads/2026/11/financial-results.pdf and can be accessed by scanning the QR Code. ForandonbehalfofBoardofDirectorsof DevyaniInternationalLimited Sd/- ManishDawar Place :Gurugram Whole-timeDirector(President&GroupCEO) Dated:2November2026 DIN:00319476 fu{¢ûk yuLxh«kRÍeÍ r÷r{xuz ((‚‚ee yykkEE yyuu™™:: yyuu÷÷0011111100SSssuu11999966……eeyyuu÷÷‚‚ee002299332299)) hrs. ykurV‚: 330, rxÙrðÞk fkuBÃ÷uõ‚, ™xw¼kR ‚fo÷, hu‚fku‚o, ðzkuËhk - 390007 R-{u÷: girishshah@chemcrux.com Vku™: 0265-2984803/2988903 ðuƒ‚kRx: www.chemcrux.com TUESDAY, NOVEMBER 3, 2026 WWW.FINANCIALEXPRESS.COM FINANCIAL EXPRESS Fusion Finance Limited 3¢ Fusi & AKUMS DRUGS AND PHARMACEUTICALS LIMITED = FUSION Ao Finance CIN: LES100DL1994PLCOG1287 CIN: L24239DL2004PLC125888 Registered address: H-1, C Block, Community Centre, Naraina Vihar, New Delhi - 110028 Regd. Office: 304, 3° Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (India) Corporate office: Plot no. 86, Institutional Sector 32, Gurugram, Haryana - 122001 Akums Corporate Office: Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Contact Person: Vikrant Sadana, Company Secretary and Compliance Officer; Tal.: +81-124-6910500 Phone: +91-11-69041000, Fax: +91-11-27023256, E-mail: akumsho@akums.net, Website: www.akums.in E-mail: companysecretary@fusionfin.com; Website: www.fusionfin.com Extract of Unaudited Financial results for the quarter and half year ended September 30, 2026 UNAUDITED (STANDALONE & CONSOLIDATED) FINANCIAL RESULTS (¥ in crore unless otherwise stated) | Quarter ended | Half year ended Year ended FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 5. | Pasticulars September | June 30, September | September September | March 31, No. | | 30,2026 | 2026 | 30,2025 | 30,2026 | 30,2025 | 2026 The Board of Directors of Akums Drugs and Pharmaceuticals Limited (“the Company™), | | Unaudited| Unaudited| Unaudited| Unaudited| Unaudited Audited For more information, on recommendation of the audit committee, at its meeting held on November 2, 2026, 3 “T.m.a_lulnc_:omr_-:.frnm t_jpelratio.nls dassi | 4581? | a1579 leB.?E!“ 8580? 1,698'53 please scan: approved the Unaudited (Standalone & Consolidated) Financial Results for the Quarter and 2 |Met Profit/(loss) for the period (before Tax, | half year ended September 30, 2026. | Exceptional and/or Extraordinary items) | 86.48 | 62,41 | (22.14) | 148.89 | 1114.39) | (62.93) The full Financial Results along with the Limited Review Report are available on the websites 3 | Met Profit/ (floss) for the period before tax (after ] Exceptional and/or Extraordinary items) | 86.48 | 62.41 | (22.14) | 146.8% | (114.39) | i52.933_ of the stock exchanges at www.bseindia.com and www.nseindia.com, and also posted on the website of the Company and can be accessed at www.akums.in/investors/financial-report/. 4 | Net Profit/(loss) for the period after tax (after | Exceptional and/or Extraordinary items) | 86.48 | 62.41 | (22.14) | 148.89 | (114.39) | 13.85 | For Akums Drugs and Pharmaceuticals Limited 5 | Total Comprehensive Income for the period Sd/- [Compri sing Profit/(loss) for the period (after tax) __and Other Comprehensive Income (after tax)] | 88,26 | 59.61__ {29.300 | 147,87 | (11913) | 1].60__ Sanjeev Jain 5 Paid up Equity Share Capital Date: November 2, 2026 Managing Director | | (face value of ¥ 10/- each) | 161.59 | 161.56 13118 | 161.58 | 13118 | 161.52 | Place: Delhi DIN: 00323433 7. [Resarvasiexciuding Revalltian Reserve) | 7208 (1939)| (22194)| 7208| (22184)| (8363) 8 | Securities Premium Account 2,38018 | 237852 | 200898 238018 200898 237804 L) | Met worth 261385 | 2,520.68 | 1,818.22 | 2.613.85 | 1,818.22 | 2,455,083 10 | Paid up Debt Capital / Outstanding Debt 593633 | 584034| 493362 593633| 4,93362| 557076 TBO Tek Limited 11 | Qutstanding Redeemable Preference Shares - =] = - tbo.com 12 | Debt Equity Ratio 2.27 232 257 2.27 2.57 2.27 CIN: L74999DL2006PLC155233 Regd. Office: Unit No. 501, 5" Floor, Worldmark-4, Asset Area No. LP-IB-04, Gateway District, Aerocity, Earnings Per Share (face value of ¥ 10/- each) Near Indira Gandhi International Airport, New Delhi-110037 B | (not annualised for quarter and half-year endec‘]_ | | | | | | | Corporate Office: Plot No. 728, Udyog Vihar Phase-V Gurugram-122016, Haryana, India [%. Raslc . | 256 | {1.69) | 9.22| l8en| 10 Tel. No.: +91124 499 8999, Email: corporatesecretarial@tbo.com, Website: www.tbo.com | | 2. Diluted: | 5.32 | 3.85 | {1.69) | 217 | {8.97) | 1M | STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS 14 | Total debts to tolal assets | 0.67 | 087 | 0.70 | 0.67 | 070 067 FOR THE QUARTER AND HALF YEAR ENDED ON SEPTEMBER 30, 2026 15 | Net profit/{loss) margin (%) 17.81% 13.62% (5.12%) 1577% | (13.02%) | 0.80% 16 | Capital Redemption Reserve 7 IS 7 IS 7 AN 7 IR 7 7N The Board of Directors of the Company, at their meeting held on November 02, 2026, approved the Unaudited Standalone & Consolidated Financial Results (“Financial Results”) of the Company For more 1?_j Debentura Redemption Reserve | MA | NA_E MNA | NA_ A | NA__ information for the Quarter and Half Year ended September 30, 2026. 1| Dabt Service Govarage Hallo, . A | N NA | A | DA | NA| please scan: The Financial Results along with the Limited [Showing first 8,000 characters — download PDF for full document]